Anti-CD38 IgGκ monoclonal antibody (Darzalex), administered subcutaneously; targets CD38 on clonal plasma cells and mediates ADCC, CDC, ADCP, and direct apoptosis.
Human IgG1κ monoclonal antibody against CD38 on clonal plasma cells; induces cell death via ADCC, CDC, ADCP, and direct apoptosis, and depletes CD38+ immunosuppressive cells.
YES
DIRECT
Binds CD38 on target cells and induces NK cell–mediated ADCC via FcγR, complement-dependent cytotoxicity (CDC), macrophage phagocytosis (ADCP), and can trigger direct apoptosis upon crosslinking.
Afucosylated humanized IgG1 monoclonal antibody targeting CCR4; induces antibody-dependent cellular cytotoxicity against CCR4-positive malignant T cells and regulatory T cells.
Afucosylated humanized IgG1 monoclonal antibody targeting CCR4 (CD194) that blocks CCR4-mediated chemokine signaling/trafficking and induces enhanced FcγRIIIa-dependent ADCC, depleting CCR4-positive malignant T cells and regulatory T cells.
YES
DIRECT
Anti-CCR4 IgG1 binds CCR4 on target cells and engages Fc-gamma RIIIa on NK/effector cells to trigger ADCC, leading to lysis/depletion of CCR4-positive malignant T cells and Tregs.
Antibody–drug conjugate targeting TROP-2 that delivers SN-38 (govitecan), a topoisomerase I inhibitor; internalization and linker cleavage release the cytotoxic payload with potential bystander effect.
Humanized anti–TROP-2 monoclonal antibody conjugated to SN-38 (topoisomerase I inhibitor). Binding to TROP-2 triggers internalization; linker cleavage releases SN-38, stabilizing Topo I–DNA complexes to cause DNA breaks and apoptosis, with potential membrane-permeable bystander killing.
YES
DIRECT
Anti–TROP-2 antibody–drug conjugate binds TROP-2, is internalized, and releases SN-38, a topoisomerase I inhibitor, causing DNA damage and apoptosis in target cells (with potential bystander effect).
An anti-HER2 antibody–drug conjugate administered IV every 6 weeks (2.2 mg/kg). The monoclonal antibody targets HER2, is internalized, and releases the auristatin-derived microtubule inhibitor Amberstatin-269 to disrupt tubulin polymerization, causing G2/M arrest and apoptosis; the antibody component may also inhibit HER2 signaling and mediate ADCC.
HER2-targeted monoclonal antibody-drug conjugate. After binding HER2 and internalization, it releases an auristatin (MMAF analog) payload that inhibits microtubule polymerization, causing G2/M arrest and apoptosis; the antibody component may also inhibit HER2 signaling and mediate antibody-dependent cellular cytotoxicity (ADCC).
YES
DIRECT
ARX788 binds HER2, is internalized, and releases an MMAF analog that inhibits microtubule polymerization, causing G2/M arrest and apoptosis; the antibody may also recruit ADCC.
Antibody–drug conjugate targeting TROP-2 that delivers SN-38 (govitecan), a topoisomerase I inhibitor; internalization and linker cleavage release the cytotoxic payload with potential bystander effect.
Humanized anti–TROP-2 monoclonal antibody conjugated to SN-38 (topoisomerase I inhibitor). Binding to TROP-2 triggers internalization; linker cleavage releases SN-38, stabilizing Topo I–DNA complexes to cause DNA breaks and apoptosis, with potential membrane-permeable bystander killing.
NO
INDIRECT
The ADC targets TROP-2 on cells, is internalized, and releases SN-38, which inhibits topoisomerase I to cause DNA damage and apoptosis. Topoisomerase I is the payload’s enzymatic target, not the antigen guiding cell targeting, so its expression alone is not directly targeted for killing.